RAFAEL HOLDINGS, INC. Debt Securities, Available-for-sale, Amortized Cost
RAFAEL HOLDINGS, INC. (RFL) had Debt Securities, Available-for-sale, Amortized Cost of $46.16 million as of 2024-10-31, per its 10-Q filed 2024-12-11.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2025-10-29
- 2024-10-31: Debt Securities, Available-for-sale, Amortized Cost $46.16M.
- 2024-07-31: Debt Securities, Available-for-sale, Amortized Cost $63.30M.
- 2024-04-30: Debt Securities, Available-for-sale, Amortized Cost $65.03M.
- 2023-07-31: Debt Securities, Available-for-sale, Amortized Cost $57.99M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2024-10-31 | $46.16M 10-Q · filed 2024-12-11 |
| 2024-07-31 | $63.30M 10-K · filed 2025-10-29 |
| 2024-04-30 | $65.03M 10-Q · filed 2024-06-14 |
| 2023-07-31 | $57.99M 10-K/A · filed 2024-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |